Nrg-Gy009
Posted Date: Sep 7, 2020
- Investigator: Thomas Herzog
- Specialties: Cancer, Ovarian Cancer
- Type of Study: Drug
This phase II/III trial studies how well pegylated liposomal doxorubicin hydrochloride with atezolizumab and/or bevacizumab work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent). The primary outcomes of this study are determining the incidences of DLTs, progression free survival, and overall survival.
Criteria:
To Be Eligible: Must Have High Grade, Recurrent, Platinum Resistant Overian Cancer, Measurable Disease, Ecog 0-2, Adequate Organ Function, No Prior Organ Transplant, No Anticancer Therapy Within 3 Weeks, No Previous Rt To Abdomen Or Pelvis, No Significant Liver Disease, No Other Malignancy Within 3 Years, No Significant Active Or Past Medical History That May Impair Participants Ability To Adhere To Study Treatment
Keywords:
Ovarian Cancer, Peritoneal Cancer
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com